聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 48 分钟 8 秒 前

Agena Bioscience Announces FDA 510(k) Premarket Clearance of the IMPACT Dx(TM) Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx(TM) System

周一, 06/16/2014 - 13:20
IMPACT Dx™ Combined Function System Will Also Be Available in the European Union SAN DIEGO, June 16, 2014 -- (Healthcare Sales & Marketing Network) -- Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., was notifi...
Diagnostics, FDA
Agena Bioscience, Sequenom, IMPACT Dx, Factor V Leiden

Varian Medical Systems to Equip Prime Healthcare Services Hospitals with Varian Technology for Image-Guided Radiotherapy and Radiosurgery

周五, 06/13/2014 - 12:57
Prime Healthcare acquires four TrueBeam™ systems as a step toward upgrading and standardizing cancer treatment services across its healthcare system PALO ALTO, Calif., June 13, 2014 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (V...
Devices, Oncology
Varian Medical Systems, radiotherapy, radiosurgery, TrueBeam

Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag (Promacta(TM)/Revolade(TM)) in Pediatric Patients with Chronic Immune Thrombocytopenia

周五, 06/13/2014 - 12:48
SAN DIEGO--(Healthcare Sales & Marketing Network)--Ligand Pharmaceuticals Incorporated (LGND) announces that its partner, GlaxoSmithKline (GSK) plc, presented the results from the Phase 3 PETIT2 study evaluating the efficacy of eltrombopag vs. placebo in p...
Biopharmaceuticals
Ligand Pharmaceuticals, GlaxoSmithKline, Eltrombopag, Promacta, Revolade

EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals

周五, 06/13/2014 - 12:42
Common stock to begin trading under "CASI" on June 16, 2014 ROCKVILLE, Md., June 13, 2014 -- (Healthcare Sales & Marketing Network) -- EntreMed, Inc. (ENMD), a clinical-stage biopharmaceutical company developing therapeutics for the treatment...
Biopharmaceuticals
EntreMed, CASI Pharmaceuticals

Theravance, Inc. Appoints George B. Abercrombie as Senior Vice President, Corporate Partnerships, Commercial

周五, 06/13/2014 - 12:35
SOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), a royalty management company, today announced the appointment of George B. Abercrombie, Senior Vice President, Corporate Partnership...
Biopharmaceuticals, Personnel
Theravance, Glaxo Group

FDA approves Bayer's Gadavist (gadobutrol) Injection as the first magnetic resonance contrast agent for evaluation of breast cancer in the United States

周四, 06/12/2014 - 18:20
Gadavist-enhanced breast MRI demonstrated superior sensitivity (range: 80-89%) for the presence and extent of malignant disease compared to unenhanced breast MRI (range: 37-73%) Sensitivity for the presence and extent of malignant breast disease ranged ...
Biopharmaceuticals, Radiology, FDA
Bayer HealthCare, Gadavist, gadobutrol, contrast agent, breast cancer

Integra LifeSciences Announces Contract with Premier, Inc.

周四, 06/12/2014 - 13:42
Will Provide Small Bone Orthopedic Implants PLAINSBORO, N.J., June 12, 2014 -- (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holding Corporation (IART) today announced that its Orthopedics and Tissue Technologies group signed a three-ye...
Devices, Group Purchasing, Orthopaedic
Integra LifeSciences

Clarus Therapeutics Secures $31.5 Million in Financing

周四, 06/12/2014 - 13:13
Announces New Appointment to Board of Directors NORTHBROOK, Ill., June 12, 2014 -- (Healthcare Sales & Marketing Network) -- Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company focused on the development and commercialization of R...
Biopharmaceuticals, Venture Capital, Personnel
Clarus Therapeutics, REXTORO

Cardiovascular Systems Announces Plans for New Corporate Headquarters

周四, 06/12/2014 - 13:08
Facility to Accommodate Anticipated Growth Company Will Remain in New Brighton, Minn. ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--Cardiovascular Systems, Inc. (CSI) (CSII), today announced plans to build a new corporate headquarters in ...
Devices, Interventional Cardiology
Cardiovascular Systems, Orbital Atherectomy

Scioderm Names Ronald Nardi, Ph.D. Chief Scientific Officer

周四, 06/12/2014 - 13:02
DURHAM, N.C., June 12, 2014 -- (Healthcare Sales & Marketing Network) -- Scioderm, Inc. today announced the addition of Ronald Nardi, Ph.D. as the company's first chief scientific officer. Key points: Dr. Nardi brings more than 35 years of experienc...
Biopharmaceuticals, Personnel
Scioderm, epidermolysis bullosa, SD-101

SoluMatrix(R) Meloxicam Demonstrates Significant Efficacy at 30 Percent Lower Doses in the Treatment of Osteoarthritis

周四, 06/12/2014 - 12:51
Phase 3 Data Presented at EULAR 2014 PHILADELPHIA--(Healthcare Sales & Marketing Network)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that sho...
Biopharmaceuticals
Iroko Pharmaceuticals, SoluMatrix, meloxicam, osteoarthritis

Aerocrine AB Announces Leadership Changes

周四, 06/12/2014 - 12:39
SOLNA, Sweden--(Healthcare Sales & Marketing Network)--Aerocrine AB (OMX Nordic Exchange: AERO) today announced that Marshall Woodworth will be appointed new Chief Financial Officer. Anders Murman will be promoted to Chief Technology Officer. Marshall W...
Devices, Personnel
Aerocrine, NIOX MINO, NIOX VERO

Tissue Regenix Announces Launch of DermaPure(TM) in the USA

周四, 06/12/2014 - 12:35
DermaPure™ targets $1.4 billion a year market for skin substitutes Distribution network now covers 80% of country Federal institution distributor appointed YORK, UNITED KINGDOM--(Healthcare Sales & Marketing Network) - Tissue Regenix Group plc (AI...
Devices, Regenerative Medicine, Wound Care, Product Launch
Tissue Regenix Group, DermaPure, dCELL , tissue scaffold

RuiYi Closes $4 Million Venture Loan from Silicon Valley Bank

周三, 06/11/2014 - 12:56
LA JOLLA, Calif. and SHANGHAI, June 11, 2014 -- (Healthcare Sales & Marketing Network) -- RuiYi, Inc., a global therapeutic innovation leader, announced today the close of a $4 million debt financing from Silicon Valley Bank to advance a pipeline of novel...
Biopharmaceuticals, Venture Capital
RuiYi

Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial

周三, 06/11/2014 - 12:50
INDIANAPOLIS, June 11, 2014 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (LLY) today announced that the Phase III REACH trial of CYRAMZA™ (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not me...
Biopharmaceuticals, Oncology
Eli Lilly, CYRAMZA, ramucirumab, liver cancer

GSK and Theravance Announce Positive Data From Two Studies Evaluating the Efficacy and Safety of Incruse(TM) Ellipta(R) When Added to Relvar(R)/Breo(R) Ellipta(R) in Patients With COPD

周三, 06/11/2014 - 12:41
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from two phase III studies, which showed that patie...
Biopharmaceuticals
Theravance, GlaxoSmithKline, COPD , Incruse Ellipta, umeclidinium

Navidea Biopharmaceuticals’ Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes in Post-Hoc Analysis

周三, 06/11/2014 - 12:23
Ability of receptor-targeted Lymphoseek to accurately target appropriate lymph nodes may lessen patient morbidity from extensive oral cavity surgery DUBLIN, Ohio--(Healthcare Sales & Marketing Network)--Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), ...
Biopharmaceuticals, Oncology
Navidea Biopharmaceuticals, Lymphoseek, radiopharmaceutical

Ivera Medical Announces Extension of Novation Agreement

周三, 06/11/2014 - 12:12
SAN DIEGO, CA--(Healthcare Sales & Marketing Network) - Ivera Medical Corporation, a certified minority-owned business, announced an extension of its agreement with Novation for the Curos® family of products. The agreement, which originally commenced o...
Devices, Group Purchasing
Ivera Medical, Novation , Curos Port Protectors, Curos Strips, Curos Tips

Bioventus Announces U.S. Debut of Feature-Rich New EXOGEN(R) Device

周二, 06/10/2014 - 15:30
DURHAM, N.C.--(Healthcare Sales & Marketing Network)--Bioventus, a global leader in active orthopaedic healing, today rolled out the next generation of its market-leading1EXOGEN® Ultrasound Bone Healing System, which includes a variety of new complianc...
Devices, Orthopaedic, Product Launch
Bioventus, EXOGEN , Ultrasound Bone Healing System

Auxogyn Receives FDA Clearance for Its Eeva(TM) System

周二, 06/10/2014 - 14:52
Breakthrough Test Provides First-of-a-Kind Objective Assessment of Embryo Development Potential MENLO PARK, Calif.--(Healthcare Sales & Marketing Network)--Auxogyn, Inc. a leader in women’s reproductive health, today announced that its first product, th...
Devices, FDA
Auxogyn, Eeva System, in vitro fertilization

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong